Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study
Trial Parameters
Brief Summary
This study is for patients with locally advanced sinonasal adenoid cystic carcinoma (SNACC), a rare and challenging cancer that tends to invade nerves and the skull base. The research aims to test a new precise treatment strategy. First, all participants will receive three sessions of "interventional chemotherapy" (transarterial chemoembolization) with the drug Epirubicin, which delivers high-dose chemotherapy directly to the tumor to shrink it as much as possible. About 4-6 weeks after the third session, doctors will use MRI scans to evaluate how well the tumor responded. Based on this response, patients will follow one of two personalized treatment paths: those whose tumors did not completely disappear will undergo surgery followed by radiotherapy; those whose tumors show complete disappearance on imaging will receive precise radiotherapy alone, potentially avoiding major surgery. This is a prospective, multicenter study. The main goals are to evaluate the safety and effectiveness of this response-adapted strategy and to see if it can improve outcomes for patients with this difficult-to-treat cancer.
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 and 70 years. 2. Histologically confirmed diagnosis of sinonasal adenoid cystic carcinoma (ACC). 3. Tumor stage T3 or T4 according to the AJCC (American Joint Committee on Cancer) 9th edition staging system. Participants with lymph node metastasis must be amenable to surgical dissection. Those with distant metastasis must have stable disease. 4. Ability to provide a sufficient volume (≥0.5 cm³) of fresh tumor tissue via biopsy or surgery for research purposes, with participant's informed consent. 5. ECOG (Eastern Cooperative Oncology Group) performance status score of 0 to 2. 6. Voluntary participation and provision of written informed consent. Good compliance, able to cooperate with treatment and follow-up. Exclusion Criteria: 1. Prior treatment with Epirubicin or any other anthracycline-based chemotherapy. 2. Prior radiotherapy to the head and neck region. 3. Administration of any other chemotherapy, targeted therapy, or immunotherapy within 4 we